222 related articles for article (PubMed ID: 33599857)
21. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
Wang R; Liu R; Zhao L; Xu D; Hu L
Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
[TBL] [Abstract][Full Text] [Related]
22. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
23. The Diagnostic Value of the Systemic Immune-Inflammation Index for Venous Thromboembolism in Lung Cancer Patients: A Retrospective Study.
Zhang L; Liu X; Yang R; Yang Y; Chen X
Mediators Inflamm; 2022; 2022():9215311. PubMed ID: 36046761
[TBL] [Abstract][Full Text] [Related]
24. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
25. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
26. Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.
Vathiotis I; Dimakakos EP; Boura P; Ntineri A; Charpidou A; Gerotziafas G; Syrigos K
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1347-1351. PubMed ID: 29806470
[TBL] [Abstract][Full Text] [Related]
27. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
28. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.
Overvad TF; Ording AG; Nielsen PB; Skjøth F; Albertsen IE; Noble S; Vistisen AK; Gade IL; Severinsen MT; Piazza G; Larsen TB
Blood Adv; 2022 May; 6(10):2967-2976. PubMed ID: 35045569
[TBL] [Abstract][Full Text] [Related]
30. Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients.
Akasaka-Kihara F; Sueta D; Ishii M; Maki Y; Hirakawa K; Tabata N; Ito M; Yamanaga K; Fujisue K; Hoshiyama T; Hanatani S; Kanazawa H; Takashio S; Arima Y; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Soejima H; Kaikita K; Matsushita K; Matsuoka M; Usuku K; Tsujita K
JACC Asia; 2021 Sep; 1(2):259-270. PubMed ID: 36338156
[TBL] [Abstract][Full Text] [Related]
31. PO-04 - A new genetic risk score for predicting venous thromboembolic events in cancer patients receiving chemotherapy.
Martín AJ; Ziyatdinov A; Rubio VC; Olmos VP; Huerta BM; Rodríguez JC; Fernández MS; de Castro EM; Caro RL; Fernández JM
Thromb Res; 2016 Apr; 140 Suppl 1():S177-8. PubMed ID: 27161691
[TBL] [Abstract][Full Text] [Related]
32. The performance of Khorana risk score for prediction of venous thromboembolism in patients with lung cancer: A retrospective cohort study.
Kizilirmak D; Fidan U; Havlucu Y
Tuberk Toraks; 2024 Jun; 72(2):114-119. PubMed ID: 38869203
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
[TBL] [Abstract][Full Text] [Related]
34. The Combination of D-dimer and Glasgow Prognostic Score Can Be Useful in Predicting VTE in Patients with Stage IIIC and IVA Ovarian Cancer.
Kubo K; Nakamura K; Okamoto K; Matsuoka H; Ida N; Haruma T; Ogawa C; Masuyama H
Acta Med Okayama; 2022 Apr; 76(2):129-135. PubMed ID: 35503440
[TBL] [Abstract][Full Text] [Related]
35. Optimal D-Dimer Cutoff Values for Diagnosing Deep Vein Thrombosis in Patients with Comorbid Malignancies.
Niimi K; Nishida K; Lee C; Ikeda S; Kawai Y; Sugimoto M; Banno H
Ann Vasc Surg; 2024 Jan; 98():293-300. PubMed ID: 37454901
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism.
Ke L; Cui S; Chen S; Hu B; Li H
Thorac Cancer; 2020 Sep; 11(9):2483-2492. PubMed ID: 32657038
[TBL] [Abstract][Full Text] [Related]
37. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
38. [Risk factors of lung cancer complicated with symptomatic venous thromboembolism].
Gong CY; Li ZW; Zhou DX; Yan H; Bao J; Ye RJ; Cao ZL; Gao ZC; Mu XL
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):454-8. PubMed ID: 27289575
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
[TBL] [Abstract][Full Text] [Related]
40. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Kim JS; Kang EJ; Kim DS; Choi YJ; Lee SY; Kim HJ; Seo HY; Kim JS
BMC Cancer; 2018 Dec; 18(1):1260. PubMed ID: 30558603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
